Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-17

Clinical Trial Update: Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1) [Phase 1]

View source ↗

Summary

A Phase 1 study comparing two oral formulations of nitisinone for hereditary tyrosinemia type I completed, with bioequivalence results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nitisinone (Nitisinone)

Snippet

Sponsor: Cycle Pharmaceuticals Ltd. | Conditions: Hereditary Tyrosinemia, Type I | Phase 1 | Status: COMPLETED | Results posted: 2016-10-17